5-s-cysteinyldopamine has been researched along with Idiopathic Parkinson Disease in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badillo-Ramírez, I; Rivas-Arancibia, S; Saniger, JM | 1 |
| Aureli, C; Cassano, T; Chichiarelli, S; Cocciolo, A; d'Erme, M; Fontana, M; Francioso, A; Gaetani, S; Mancini, P; Martire, S; Masci, A; Mosca, L; Romano, A | 1 |
| Goldstein, DS; Holmes, C; Jinsmaa, Y; Kopin, IJ; Sharabi, Y; Sullivan, P | 1 |
| Asmaro, K; Beningo, KA; Hermiz, DJ; Mehta, NJ; Njus, D; Njus, MM; Saleh, AH | 1 |
| Corona, G; Spencer, JP; Vauzour, D | 1 |
| Cheng, FC; Chia, LG; Dryhurst, G; Kuo, JS | 1 |
| Dryhurst, G; Li, H; Shen, XM | 2 |
| Dryhurst, G; Li, H | 1 |
| Carlsson, A; Fornstedt, B | 2 |
2 review(s) available for 5-s-cysteinyldopamine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: Implications for Parkinson's disease.
Topics: alpha-Synuclein; Biomarkers; Dopamine; Dopaminergic Neurons; Endoplasmic Reticulum Stress; Humans; Metabolic Networks and Pathways; Mitochondria; Nerve Tissue Proteins; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Pars Compacta; Sulfur | 2019 |
Possible mechanisms underlying the special vulnerability of dopaminergic neurons.
Topics: Aged; Aged, 80 and over; Animals; Brain; Cell Survival; Dopamine; Humans; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine | 1991 |
9 other study(ies) available for 5-s-cysteinyldopamine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Biogenic Monoamines; Brain; Cell Line, Tumor; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Glutathione; Glutathione Disulfide; Humans; Male; Mice; Neuroblastoma; Oxidative Stress; Oxidopamine; Parkinson Disease; Protein Carbonylation; Protein Disulfide-Isomerases | 2014 |
Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Catechols; Dihydroxyphenylalanine; Dopamine; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; PC12 Cells; Putamen; Rats | 2016 |
Hypochlorite converts cysteinyl-dopamine into a cytotoxic product: A possible factor in Parkinson's Disease.
Topics: Animals; Cell Survival; Cytotoxins; Dopamine; Humans; Hypochlorous Acid; Models, Biological; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; PC12 Cells; Peroxidase; Rats; Superoxides; Taurine | 2016 |
Caffeic acid, tyrosol and p-coumaric acid are potent inhibitors of 5-S-cysteinyl-dopamine induced neurotoxicity.
Topics: Animals; Caffeic Acids; Cells, Cultured; Coumaric Acids; Dopamine; Flavonoids; Mice; Neurons; Neuroprotective Agents; Parkinson Disease; Phenylethyl Alcohol; Propionates; Wine | 2010 |
Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Chromatography, High Pressure Liquid; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Parkinson Disease; Reference Values | 1996 |
Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of
Topics: Animals; Brain; Catalysis; Dopamine; Electron Transport Complex I; Enzyme Inhibitors; Free Radical Scavengers; Glutathione; Male; Mitochondria; NAD(P)H Dehydrogenase (Quinone); NADH, NADPH Oxidoreductases; Oxidation-Reduction; Parkinson Disease; Rats; Rats, Sprague-Dawley; Thiazines | 1998 |
Oxidative metabolites of 5-S-cysteinyldopamine inhibit the alpha-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease.
Topics: Animals; Antioxidants; Brain; Catalase; Dopamine; Electron Transport Complex IV; Enzyme Inhibitors; Intracellular Membranes; Ketoglutarate Dehydrogenase Complex; Male; Mitochondria; Oxidation-Reduction; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Thiazines | 2000 |
Oxidative metabolites of 5-S-cysteinyldopamine inhibit the pyruvate dehydrogenase complex.
Topics: Animals; Ascorbic Acid; Catalase; Dopamine; Energy Metabolism; Glutathione; Intracellular Membranes; Male; Mitochondria; Neurons; Oxidative Stress; Parkinson Disease; Pyruvate Dehydrogenase Complex; Rats; Rats, Sprague-Dawley; Substantia Nigra; Superoxide Dismutase; Thiazines | 2001 |
Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catechols; Dopamine; Guinea Pigs; Humans; Oxidation-Reduction; Parkinson Disease; Time Factors | 1991 |